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referred	 to	 specialized	 centres.2-4	 PA	 is	 associated	 with	 increased	
cardiovascular	 morbidity	 and	 mortality	 as	 compared	 to	 equivalent	
	degrees	 of	 essential	 hypertension,5-7	 and	 hence,	 early	 recognition	
and	treatment	of	PA	is	imperative.8	PA	is	traditionally	subclassified	as	
either	 bilateral	 hyperaldosteronism	 (BHA)	 or	 aldosterone	 producing	Richard	J.	Auchus	and	Adina	F.	Turcu	contributed	equally	to	this	work.
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adenomas	(APA),1	although	some	patients	have	features	of	both	sub-
types.	 Correct	 subclassification	 of	 PA	 is	 essential,	 as	 patients	 with	










findings	 in	 resected	 adrenals	 from	patients	with	 PA	 underscore	 the	
limitations	of	adrenal	 imaging	 in	 identifying	the	source(s)	of	aldoste-
rone	excess.
Adrenal	 vein	 sampling	 (AVS)	 is	 considered	 the	 most	 accurate	
method	 for	 determining	whether	 one	 or	 both	 adrenals	 produce	 ex-
cess	 aldosterone.8	 Aside	 from	 patients	 younger	 than	 35	years	with	
unequivocal	 PA,13,14	 cross-	sectional	 adrenal	 imaging	 findings	 are	
frequently	 discordant	with	 the	 aldosterone	 source	 as	 lateralized	 by	
AVS.15-19	 Nevertheless,	 resolution	 of	 PA	 after	 unilateral	 adrenalec-








of	 treatment	 failure.	While	 clinical	 improvement	 is	 achieved	 in	 the	
majority	of	PA	cases	treated	surgically,9,13,22-24	data	regarding	contrib-
utors	 to	 surgical	 treatment	 failure	 have	been	 scarce.	 In	 the	 present	
study,	we	aimed	to	identify	the	pitfalls	in	PA	subclassification,	leading	
to	the	absence	of	PA	improvement	after	surgical	treatment.
2  | PATIENTS AND METHODS
2.1 | Study participants




imaging,	 AVS	 data,	 pathology	 reports	 and	 postoperative	 follow-	up	
records	were	 retrospectively	 reviewed.	 The	 antihypertensive	medi-
cations	were	converted	to	a	standardized	daily	defined	dose	 (DDD)	
according	 to	 the	 WHO	 ATC/DDD	 Index.25	 Immunohistochemistry	
studies	 were	 conducted	 on	 paraffin-	embedded	 adrenal	 tissues	 in	






Plasma	 aldosterone	 concentration	 (PAC)	 and	 plasma	 renin	 activ-
ity	 (PRA)	 were	 measured	 for	 case	 detection	 of	 PA,	 and	 screening	
was	positive	in	164/170	(96.5%)	of	patients,	based	on	a	PAC	(ng/L)/
PRA	 (μg/L/h)	 ratio	 (ARR)	≥200,	PAC	>100	ng/L	and	PRA	<1	μg/L/h.	
In	125/170	 (73.5%)	patients,	 the	diagnosis	was	confirmed	based	on	
oral	 sodium	 loading	 test	 (followed	by	a	24-	hour	urinary	aldosterone	
>12	μg),	 saline	 infusion	 test	 (PAC	 >100	ng/L	 at	 4	hours),	 or	 a	 sup-
pressed	PRA	(<1.0	μg/L/h)	with	spontaneous	hypokalaemia	and	PAC	
>200	ng/L.8	 Six	 patients	 with	 a	 high	 clinical	 index	 of	 suspicion	 did	
not	meet	ARR	screening	criteria	but	were	included	due	to	inability	to	
discontinue	 interfering	 medications.	 PAC	 was	 measured	 by	 a	 com-




5.8 μg/L/h).	 Serum	 cortisol	 was	 measured	 by	 a	 competitive	 chemi-
luminescent	 immunoassay	 on	 a	 Siemens	 ADVIA	 Centaur	 analyzer,	
with	CV	of	5.1%-	7.1%.	Urinary	aldosterone	was	measured	by	 liquid	
chromatography-	tandem	 mass	 spectrometry	 (LC-	MS/MS)	 at	 Mayo	
Medical	Laboratories.
Because	patients	with	unilateral	dominance	of	PA	might	still	have	
milder	 autonomous	 aldosterone	 production	 from	 the	 contralateral	
side,	we	focused	on	patients	with	lack	of	PA	improvement	after	sur-
gery,	 rather	 than	 on	PA	 cure.	The	 absence	 of	 PA	 improvement	was	



















We	 assessed	 the	 aldosterone	 synthetic	 capacity	 of	 the	 surgically	
	removed	 adrenal	 tissue	 in	 patients	 who	 failed	 surgical	 treatment	
and	 in	patients	with	unsuccessful	 access	of	one	AV.	Localization	of	
CYP11B2	 and	 17α-	hydroxylase/17,20	 lyase	 (CYP17A1,	 an	 enzyme	
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involved	 in	 glucocorticoid	 and	 androgen	 synthesis)	 expressing	 cells	
was	 assessed	 by	 immunohistochemistry,	 using	 corresponding	 anti-	
human	antibodies	(anti-	CYP11B2,	mouse;	1:1500,	Millipore,	Billerica,	





evaluated	using	the	Mann-	Whitney	U-	test.	A	P value < .05	was	con-
sidered	significant.
3  | RESULTS
3.1 | Demographic and diagnostic data
Between	 January	 2009	 and	August	 2016,	 208	 patients	 underwent	
AVS	 in	 our	 centre.	Of	 these,	 38	 patients	 referred	 directly	 to	 AVS,	
without	clinical	records	available	for	review,	were	excluded	(Figure	1).	
Of	the	remaining	170	patients,	101	(59%)	were	men.	The	median	age	
of	 all	 participants	was	54	 (range,	30-	79).	AVS	was	 considered	 suc-
cessful	(based	on	SI	criteria	defined	in	Methods)	in	122	(72%)	and	159	
patients	 (94%)	before	and	after	cosyntropin	administration,	 respec-
tively	 (Figure	1).	Unilateral	PA	was	diagnosed	 in	66/122	 (54%)	 and	
87/159	(55%)	patients	before	and	after	cosyntropin	administration,	
respectively.	Contralateral	 suppression	was	present	 in	50/66	 (75%)	
patients	and	82/87	(94%)	patients	with	unilateral	PA	before	and	after	
cosyntropin	administration,	respectively.	In	total,	16	of	the	159	(10%)	
successfully	 catheterized	 patients	 had	 discordant	 lateralization	 be-




Because	 catheterization	 is	 less	 often	 successful	 without	 co-
syntropin	administration,	AVS	data	after	cosytropin	administration	
have	been	preferentially	 used	 for	 clinical	 decisions	 in	 our	 centre,	
and	PA	will	 be	 further	 referred	 to	 as	 unilateral	 or	 bilateral	 based	
on	these	results,	unless	otherwise	specified.	 In	unilateral	PA,	me-
dian	PAC	(330	ng/L	vs	220	ng/L,	P < .001)	and	ARR	(1970	vs	870,	
P < .001)	were	 higher,	 and	 PRA	was	 lower	 (0.1	μg/L/h	vs	 0.3	μg/
L/h,	P = .007)	than	in	bilateral	PA	(Table	1).	Hypokalaemia	was	more	
frequent	 in	 patients	with	 unilateral	 PA	 (97%)	 than	 in	 those	with	
bilateral	PA	(75%).
Adrenal	CT	was	 performed	 in	 158	patients	 (Figure	2).	Unilateral	
adrenal	 abnormalities	 were	 diagnosed	 in	 114/158	 (72%)	 patients:	
single	nodule	 in	93	patients;	multiple	nodules	 in	 two	patients;	nod-
ules	and	underlying	hyperplasia	in	four	patients;	unilateral	thickening	
alone	in	15	patients.	Bilateral	adrenal	nodules	and/or	hyperplasia	were	
observed	 in	24	patients	 (15%).	CT	findings	coincided	with	the	 later-
alization	determined	by	AVS	 in	80/158	(51%)	patients	 (Figure	2).	Of	
117	patients	with	adrenal	nodules,	51	patients	were	evaluated	for	au-
tonomous	cortisol	 synthesis;	 five	patients	had	a	 cortisol	>50	nmol/l	





























Basal	PAC	(ng/L)a 330* [210- 460] 220 [160- 290]










In	 total,	 55	 (32%)	 patients	 underwent	 unilateral	 adrenalectomy,	
	either	 total	 (52)	 or	 partial	 (3).	 Of	 the	 remaining	 37	 patients	 with	
unilateral	PA,	24	were	subsequently	managed	at	other	 institutions,	
and	 in	 the	 other	 13	 patients,	 surgery	 was	 postponed	 for	 various	
reasons,	 including	 physician’s	 recommendations	 or	 personal	 pref-
erence.	Postoperative	 follow-	up	 ranged	 from	5	days	 to	20	months	



















To	understand	 the	 pathophysiology	 of	 poor	 clinical	 outcomes	 after	
adrenalectomy,	as	well	as	successful	outcomes	in	cases	with	incom-
plete	 AVS	 data,	 we	 performed	 immunohistochemical	 staining	 for	
CYP11B2	 on	 the	 adrenal	 glands	 from	 patients	 who	 failed	 surgical	
treatment	 (two	patients;	 for	 the	 third,	 pathology	 specimen	was	not	
available)	and		patients	in	whom	AVS	failed	unilaterally	(four	patients).
In	the	two	patients	with	available	pathology	specimens	who	had	




















ard”	 for	 lateralization	of	PA.8,16,27	The	basis	 for	 recommending	AVS	
in	 all	 patients	with	 PA	 older	 than	 35	who	might	 consider	 surgery8 
has	emerged	from	numerous	studies	demonstrating	poor	correlation	
of	 AVS	 with	 cross-	sectional	 imaging.13,14,16	 Previous	 studies	 have	
largely	focused	on	success	rates	after	adrenalectomy,	but	the	cases	
with	 absent	 clinical	 benefit	 after	 surgery	have	been	poorly	 studied.	
Published	data	suggest	that	both	CT	and	AVS	are	imperfect	tools	for	
PA	subclassification.13,20	In	the	present	study,	we	sought	to	identify	






























lateralization	 vary	 widely	 among	 centres.21,30,31	 In	 our	 institution,	
samples	 are	 routinely	 obtained	 both	 before	 and	 after	 cosyntropin	





and	 after	 cosyntropin	 administration,	 although	 10%	 of	AVS	 studies	
yielded		discrepant	results.	In	total,	6/16	patients	with	discordant	pre-	
vs	 postcosyntropin	AVS	 lateralization	 had	 adrenalectomy:	 one	who	
lateralized	only	before	and	five	who	lateralized	only	after	cosyntropin.	








Adrenalectomy	 was	 performed	 in	 three	 patients	 with	 unilateral	
AVS	 failure	 but	who	demonstrated	 suppression	 of	 aldosterone	 pro-
duction	in	the	successfully	catheterized	side	as	compared	to	IVC.	All	




























































































































































































































































































































































































































































































While	 several	 caveats	 in	 AVS	 technique	 and	 interpreta-
tion13,15,21,38,39	 require	 further	 clarification,	 we	 have	 not	 identified	
any	cases	with	absent	clinical	benefit	after	AVS-	guided	total	adrenal-
ectomy.	The	 superiority	of	AVS	 in	PA	has	been	 recently	questioned	
by	Dekkers	and	colleagues,	who	randomly	assigned	200	patients	with	
PA	to	undergo	subclassification	by	either	CT	or	AVS.20	At	1-	year	fol-
low-	up,	 there	 was	 no	 statistical	 difference	 in	 the	 antihypertensive	
treatment	 intensity	 between	 the	 two	 groups,	 despite	 the	 fact	 that	
the	agreement	between	AVS	and	CT	findings	was	only	50%.	Of	 the	
92	patients	(46	in	each	group)	who	underwent	surgery,	PA	was	per-
sistent	 in	nine	 (20%)	vs	 five	 (11%)	patients	with	CT-	or	AVS-	guided	
surgery,	respectively.	These	failure	rates	are	much	higher	than	in	other	
reports.11,13,22	Nonetheless,	 the	 study	was	 underpowered	 to	 detect	






























for	postoperative	 follow-	up,	 remain	necessary	 to	 clarify	 the	optimal	
approach	to	PA	lateralization	in	cases	amenable	to	surgical	treatment.
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